1Q1
2
3Q2
4
5Q3
6
7
8
9
10
11
12
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
ava i l ab l e a t www.sc i enced i r ec t . com
C l i n i ca l Immuno logy
www.e l sev i e r . com/ l o ca t e / y c l im
Clinical Immunology (2014) xx, xxx–xxx
YCLIM-07389; No. of pages: 10; 4C:
F
Fetal-onset IPEX: Report of two families andreview of literature
OMariana Moraes Xavier-da-Silva a, Carlos A. Moreira-Filhob, Edson Suzuki c,Francy Patriciod, Antonio Coutinhoe, Magda Carneiro-Sampaiob,⁎
OPRa Universidade Estadual de Londrina (UEL), Londrina, PR, Brazil
b Department of Pediatrics, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, SP, Brazilc Faculdade de Medicina Estadual de Marilia (FAMEMA), Marília, SP, Brazild Dept of Pathology, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazile Instituto Gulbenkian de Ciência, Oeiras, Portugal
DReceived 8 August 2014; accepted with revision 18 December 2014
C
⁎ Corresponding author at: Instituto dada FMUSP, Av. Dr. Enéas Carvalho de AguSP, Brazil.
E-mail address: [email protected] (
http://dx.doi.org/10.1016/j.clim.2011521-6616/© 2014 Published by Elsevi
Please cite this article as: M.M. Xavier-http://dx.doi.org/10.1016/j.clim.201
E
ECTKEYWORDS
Fetal IPEX;Primary immunodeficiency;FOXP3;Type I diabetes mellitus;Miscarriages;Fetal hydrops
Abstract Early-life autoimmunity is an IPEX characteristic, however intrauterine forms hadnot yet been described. Here, two unrelated families with clear evidence of fetal-onset IPEX arereported. One had 5 miscarriages of males in two generations, and a newborn presenting type-1diabetes mellitus immediately after birth, diarrhea, thrombocytopenia, eczematous dermatitis,eosinophilia, high IgE levels and autoantibodies to pancreatic islet antigens at 4-days-old.Maternal serology was negative. He presented a FOXP3 mutation, c.1189CNT, p.Arg397Trp,previously described only in another family with IPEX at birth. The second family had severalmiscarriages of males in three consecutive generations and a novel FOXP3 c.319_320delTC
ORR
mutation was observed in two miscarried monochorionic twin male fetuses. These twins died at21 weeks of gestation due to hydrops, and CD3+ infiltrating lymphocytes were found in theirpancreas. We demonstrate that: i) IPEX may develop in fetal life; and ii) c.1189CNT andc.319_320delTC mutations are associated with early-onset phenotype.© 2014 Published by Elsevier Inc.
Criança—Hospital das Clínicasiar, 647, 05403-900 São Paulo,
M. Carneiro-Sampaio).
4.12.007er Inc.
da-Silva, et al., Fetal-onset IPEX4.12.007
43
44
45
46
47
UN1. Introduction
Immune dysregulation, polyendocrinopathy, enteropathy,x-linked (IPEX) syndrome is a rare monogenic primaryimmunodeficiency (PID), characterized by early-onset
48
49
50
51
52
: R
life-threatening multisystemic autoimmunity [1–4]. IPEXsyndrome is caused by mutation of FOXP3, mapped onXp11.23, which codifies for the forkhead box protein 3(FOXP3) [5,6]. The transcription-repressor FOXP3 was shownto play a key role in the differentiation and function ofCD4+CD25+ natural regulatory T cells (Tregs), that hadproven to be essential for the establishment and mainte-nance of natural tolerance [7–10]. In IPEX, the carriermothers are healthy, even those presenting lower Treg cellnumbers in peripheral blood [3,4].
eport of two families and review of literature, Clin. Immunol. (2014),
T
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
2 M.M. Xavier-da-Silva et al.
RREC
IPEX typically manifests very early in life: symptom onsetoccurs in the first year of life in 93% of the cases [4]. Part ofthe patients presents clinical features already at birth ordevelops symptoms shortly after birth, however intrauterineIPEX has not been well characterized. The most commonIPEX findings are enteropathy (around 95% of the patients),type-1 diabetes mellitus (65%), skin disease, commonlyatopic-like dermatitis (65%), sepsis or recurrent infections(37%), cytopenias (31%), and thyroiditis (20%) [4]. Failure tothrive has been described in most patients. Hyper IgE levelsand eosinophilia have been identified in almost all patientsin whom these analyses were performed. Less commonadditional features include pneumonitis, nephritis, hepati-tis, vasculitis, arthritis, myositis, bronchial asthma, alopeciaas well as lymphadenopathy and splenomegaly. Tissuelesions are caused both by autorreactive T lymphocytesand by autoantibodies [11,12]. These disorders often appearsequentially rather than simultaneously, and the affectedorgan spectrum varies substantially from patient to patient[3]. The life expectancy of patients with IPEX syndromewithout hematopoietic stem cell transplant rarely extendsbeyond infancy.
The Human Gene Mutation Database (http://www.hgmd.org/) scores 64 different mutations in FOXP3 until 2014.Database and literature reviews show that most of theaffected individuals have mutations altering the C-terminalforkhead DNA-binding domain of the protein [2,4,13].Genotype–phenotype correlations – considering diseaseseverity, age of onset, target organs – have been difficultto establish in IPEX, with suggestions that environmental andepigenetic factors might participate in determining clinicalpicture and outcome. Clinical manifestations may be highlyheterogeneous in patients with the same mutation, differingeven within the same family [14].
In this article, we describe two unrelated IPEX familieswith clear evidence of intrauterine disease onset, charac-terized by autoimmune diabetes mellitus present at birth,history of multiple miscarriages of males – some of thosecases were due to hydrops, and two miscarried twinspresented CD3+ infiltrating lymphocytes in the pancreas –prematurity and restriction of intrauterine growth. Aliterature review was conducted in search of independentobservations of fetal-onset IPEX.
O 154155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
UNC2. Patients and methods
2.1. Study subjects
2.1.1. Family 1The proband was a male infant, born after 36 weeks ofgestation, without a known cause for prematurity, in goodvital conditions, but presenting intrauterine growth restric-tion, low weight of 2160 g (Z score b −3) and length of46 cm (Z score b −2) [15], light meconium amniotic fluid,and a very thin umbilical cord. Hyperglycemia was observedat the first hour of life: shortly after birth, after receivingmaternal milk, his capillary glycemia was 130 mg/dL,170 mg/dL after 1 h, and reaching 300 mg/dL within 6 h.Although receiving intravenous insulin infusion in theneonatal intensive care unit, glycemia remained difficultto control varying in a range of 30 to 480 mg/dL. Anti-GAD
Please cite this article as: M.M. Xavier-da-Silva, et al., Fetal-onset IPEX: Rhttp://dx.doi.org/10.1016/j.clim.2014.12.007
ED P
RO
OF
and anti-islet (ICA) antibodies were positive, with lowpeptide C at the 4th day of life, whereas maternal serumwas negative for both analyses. Immediately after birth healso presented tachydyspnea, and needed mechanicalventilation for 50 days due to respiratory distress. He alsohad feeding intolerance since the first hours of life, andevolved to watery diarrhea, sometimes with melena feces.Generalized pruritic desquamating dermatitis was observedsince the first days of life. He presented neonatal sepsis andwas treated with broad spectrum antibiotics and anti-fungaldrugs. He also had recurrent respiratory tract infections.Microbiological studies found Staphylococcus aureus (isolat-ed from a blood sample), Klebsiella pneumoniae (isolatedfrom urine, and probably a nosocomial infection) andCandida sp. (isolated from oral and rectal swabs). Labora-tory findings showed: hemoglobin level of 7.1 g/L (positiveCoombs test), thrombocytopenia (4000 platelets/mm3),leukocytosis of 18,000 cells/mm3 with 40% lymphocytes, CD4+cells: 874/mm3 (normal: 1580–4850) and CD8+: 206/mm3
(normal: 680–2470), eosinophilia (34%); albumin level of2.5 mg/dL; IgE N 2000 IU/mL (normal ≤ 17 IU/mL) and IgA,IgG and IgM were within normal range for age; normal thyroidfunction. Hewas dependent on red cell transfusions tomaintainan adequate hemoglobin level, and had also received transfu-sions of platelets.
A presumptive diagnosis of IPEX was given, and the patientwas treated with immunosuppressors tacrolimus and cyclo-sporine. After immunosuppression, he had hepatomegaly andhepatitis due to drug toxicity with high levels of AST (480 U/L)and ALT (390 U/L), as well as gamma-GT (1250 U/L). When8 months old, the FOXP3 mutation having been confirmed, hereceived hematopoietic stem cell transplantation (bonemarrow from a matched unrelated donor), but died due tosepsis complications (lung bleeding) 7 days after transplanta-tion. Before transplantation, his weight was 3650 g.
The proband was the third child of a non-consanguineousItalian-descent family. His mother had a first baby who is ahealthy 4 year-old girl, but her second gestation ended up asa miscarriage of a male fetus with hydrops, at the 27th weekof gestation. Maternal family history revealed multiple maleinfant deaths: mother's sister had 2 miscarriages (bothmales) and the grandmother had 3 miscarriages of males(Fig. 1).
DNA sequencing analysis of FOXP3 (see the descriptionbelow) revealed that patient III-3 (Fig. 1) had mutation inexon 12. The mutation was a substitution of cytosine forthymine at nucleotide position 1189 (c.1189CNT), resultingin the substitution of arginine for tryptophan (p.Arg397Trp).The patient's mother and grandmother are heterozygouscarriers of the c.1189CNT mutation. Probably the patient'saunt, who had two miscarriages of male fetuses, may also bea heterozygous carrier. This mutation was firstly describedby Wildin et al. [6] and Levy-Lahad and Wildin [17] in two fullbrothers and their maternal half-brother, all born withdiabetes mellitus type-1, enteropathy, hypothyroidism andthrombocytopenia. The two eldest patients died at a fewweeks of age and the third, treated more promptly, diedafter 5 months.
2.1.2. Family 2The proband (IV-2 in Fig. 2) was a male infant, born at31 weeks of gestational age, without a known cause for
eport of two families and review of literature, Clin. Immunol. (2014),
T
F
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
Figure 1 Heredogram of the family 1. Triangle indicates miscarriage; bold P indicates the proband; P inside the circle indicatescurrent pregnancy.
3Fetal-onset IPEX: Report of two families and review of literature
RREC
prematurity, weighting 1500 g. He had meconium in amni-otic fluid and presented untreatable diarrhea since the firsthours of life, failure to thrive and precocious sepsis. He diedafter 51 days of life due to complications of sepsis. Apresumptive diagnosis of IPEX was given only after death.
The proband's mother had a previous male baby, also bornwith 31 weeks of gestational age, and with approximately1500 g, and also with meconium in amniotic fluid. He diedafter 2 h of life without a known cause. After these twopreterm babies, she got pregnant of two monochorionicmale twins and had a miscarriage at 21 weeks of gestation.Each of the fetuses weighted around 290 g and bothpresented hydrops with congestive heart failure (no congen-ital cardiac anomaly was detected). Necropsy revealedgeneralized edema, ascites, bilateral pleural effusions, andmyocardial lesions (edema in the myocardium with areas ofischemic necrosis of myocytes), besides lesions of anoxia.The pathological findings were quite similar in the twofetuses. The skin was extremely pale. No abnormalities werefound in the gastrointestinal tract. The liver had markeddegree of chronic passive congestion with zone 3 necrosis,hemorrhagic areas, and diffuse foci of hematopoiesis. Adiffuse CD3+ lymphocytic interstitial infiltration, containingCD4+ and CD8+ cells, was observed in the pancreaticparenchyma (Figs. 3A, B and C). The spleen presentedintense hematopoiesis with white pulp depletion. Thymicarchitecture and cellularity in HE staining preparations were
UNCO
Figure 2 Heredogram of the family 2. Triangle indicates miscarricurrent pregnancy.
Please cite this article as: M.M. Xavier-da-Silva, et al., Fetal-onset IPEX: Rhttp://dx.doi.org/10.1016/j.clim.2014.12.007
ED P
RO
Oconsidered normal for gestational age (Fig. 3D). Bleeding ofbrain ventricles was observed in both fetuses.
The proband's family was non-consanguineous and alsohad an Italian-descent. Maternal familial history revealedseveral miscarriages of males in three consecutive genera-tions (Fig. 2).
FOXP3 sequencing analysis revealed a mutation at thebeginning of exon 4 in the twin fetuses (individuals IV-3 andIV-4 in Fig. 2): a two base pair deletion (c.319_320delTC)altering the translation frameshift (p.(Ser107/Asnfs*204))predicted by computational analysis using GeneDoc(v. 2.7.000, www.psc.edu/biomed/genedoc). The mother,maternal grandmother, the sister and a first cousin of themother (Fig. 2) are carriers of the same mutation. Thismutation has not been previously described.
The present study was approved by the institutionalethics committee (process 1059/2009).
2.2. FOXP3 gene analysis methodology
Genomic DNA was extracted from peripheral leukocytesusing standard procedures, using QIAamp DNA blood Midi Kit(Qiagen, Hilden, Germany) following manufacturer's instruc-tions. Sequences including all intron–exon boundaries of 11coding exons and the coding part of exon 12 were amplifiedby PCR using the primers and cycling temperatures described
age; bold P indicates the proband; P inside the circle indicates
eport of two families and review of literature, Clin. Immunol. (2014),
TED P
RO
OF
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
Figure 3 Necropsy/histopathological findings in the miscarried male twins (individuals IV. 3 and IV.4 in Fig. 2) carrying the FOXP3mutation c.319_320delTC. In A: pancreas with a diffuse interstitial infiltration of CD3+ lymphocytes that appear in brown(immunoperoxidase, CD3, 400X). B: CD4+ cells (400X); C: CD8+ cells (400X). In D: thymus had normal aspect considering theirgestational age (hematoxilin-eosin, 100X).
4 M.M. Xavier-da-Silva et al.
UNCO
RRECby Kobayashi et al. [16]. The sequencing reactions were
performed using the Big Dye Terminator v3.1 Cycle Sequenc-ing Kit (catalog no. 4337455, Applied Biosystems, Austin,Texas) and precipitated with the Big Dye XTerminatorPurification Kit (catalog no. 4376486, Applied Biosystems,Austin, TX) following the manufacturer's instructions. Singlestrand sequencing was carried out using standard methodson an ABI 3130xl sequencer (Applied Biosystems, Forest City,CA). Sequences were aligned using the GeneiousPro 5.1.7®software. Detection of altered sequences was performedemploying the Mutation Surveyor (version 3.10) software andthe reference FOXP3 gene sequence deposited under NCBIReference Sequence NG_007392.1.
3. Review of literature
We reviewed all articles on IPEX cases published in PubMedlisted journals (2000-14) searching evidence for diseasedevelopment in utero: miscarriages, presence of symptomsat birth, prematurity and low birth weight. We found a totalof 130 reported cases, all with identified FOXP3 mutations[1,2,5,6,11,12,14,16–67].
3.1. Miscarriages
In a recent and extensive review, Barzaghi et al. [4]mentioned that multiple spontaneous abortions in maternal
Please cite this article as: M.M. Xavier-da-Silva, et al., Fetal-onset IPEX: Rhttp://dx.doi.org/10.1016/j.clim.2014.12.007
family may be found in IPEX familial histories. Yet, we couldfind only a few descriptions of miscarriages in the literature,and none of multiple miscarriages. In the large familydescribed by Powell et al. in 1982 [68], where a FOXP3mutation was later identified, there were one miscarriageand one stillbirth. Unfortunately, there is no mention to thegender of these individuals, who were not included amongthe 17 males deceased in the first years of life in that family.In the IPEX family from Morocco described by Baud et al.[21], the mother, who was a carrier of F371C mutation, had7 pregnancies, with an unexplained abortion during thefourth month of gestation, without description of gender.Wildin et al. [1] reported a child with IPEX diagnosed at13 years of age (1040GNA), whose mother experienced onemiscarriage (gender unknown). In one of the familiesreported by Harbuz et al. [54], there is one miscarriage,without mention to the gender. In other IPEX families withdetailed described pedigrees, miscarriages are not men-tioned, or even explicitly denied, in the description offamilial history [5,17,19,20,46,51].
3.2. IPEX cases with clinical manifestations at birth
Most IPEX patients are born at term after an uneventfulpregnancy, with normal weight and length, and withoutpathological features. However, considering the 96 casesfrom literature with information on “age of onset”, in 11 of
eport of two families and review of literature, Clin. Immunol. (2014),
UNCO
RRECTED P
RO
OF
Table 1t1:1 IPEX patients with symptoms at birth or in utero‡.t1:2t1:3 Pt Mutation Manifestations
at birth orin utero‡
Gestationalage (weeks)
Birthweight
Enteropathy T1DM Skin features Cytopenias Other manifestations Outcome Refs
t1:4 1 a c.1189CNT Eczema 32 2000 g(Zb−2)
+ + Eczema ITP Atonic gut, peritonitis,hypothyroidism
Death at19 days
[1,6,17]
t1:5 2 a c.1189CNT Cachexia, T1DM 37 1350 g(Z b−3),SIGR
+ + no ITP Polyhydramnios,peritonitis
Death at5 weeks
[1,6,17]
t1:6 3 a c.1189CNT T1DM 36 2090 g(Z b−2)
+ + na no Polyhydramnios andmeconium in amnioticfluid, infections
Death at5 months
[1,6,17]
t1:7 4 b c.1-7GNT Hyperglycemia 35 1370 g(Z b−3)
+ + no no Caesarean section dueto SIGR, hypothyroidism
Death at54 days
[29]
t1:8 5 b c.817-1GNA Diarrhea 30 na + + Rash no Copious intestinaldischargeimmediately after birth
Death at79 days
[34]
t1:9 6 b c.1045-3CNG Generalizedeczema
At term Normal + + Eczema AIHA Hypothyroidism,infections
Death at11 month
[11]
t1:10 7 c.1150GNA Watery diarrhea 34 na + + Exfoliativedermatitis
Pancytopenia Hypothyroidism, renalfailure
Death at7 weeks
[46]
t1:11 8 b c.1222GNA T1DM 36 2400 g(Z b−2)
no + no no Nephrotic syndrome Alive at15 years
[51]
t1:12 9 c.227delT T1DM 33 1590 g(Z b−2)
+ + no AIHA, ITP, AIN Hypothyroidism,infections
Death at8 months
[51]
t1:13 10 b g.560CNT Diarrhea na na + no “Skin disease” ITP Hyperthyroidism,gastritis
Death at14 months
[14]
t1:14 11 b c.1121TNG Eczema na na + no Eczema AIHA, ITP Allergy Death at8 years
[14]
t1:15 III.3 Fig 1 c.1189 CNT T1DM 36 2160 g(Z b−3)
+ + Psoriasiformdermatitis
AIHA, ITP Meconium in amnioticfluid, sepsis
Death at8 months
Thisarticle
t1:16 IV.3 Fig 2 c.319_320delTC
Hydrops‡ Miscarriageat 21 weeks
290 g na PancreaticCD3+ cellinfiltration
Pale skin Anemia Edema, ascites Miscarriage Thisarticle
t1:17 IV.4 Fig 2 c.319_320delTC
Hydrops‡ Miscarriageat 21 weeks
290 g na PancreaticCD3+ cellinfiltration
Pale skin Anemia Edema, ascites Miscarriage Thisarticle
a Patients from the same family; Z: Z score.t1:18b The only description of the mutation in literature; T1DM: type-1 diabetes mellitus; SIGR: severe intrauterine growth restriction; na: not available; AIHA: autoimmune hemolytic anemia;
ITP: immune thrombocytopenia; AIN: autoimmune neutropenia.t1:19
5Fetal-onset
IPEX:Report
oftw
ofam
iliesand
reviewof
literature
Pleasecite
thisarticle
as:M.M
.Xavier-da-Silva,etal.,Fetal-onsetIPEX:Report
oftwofam
iliesand
reviewofliterature,C
lin.Immunol.(2014),
http://dx.doi.org/10.1016/j.clim.2014.12.007
T
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335Q4
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
6 M.M. Xavier-da-Silva et al.
REC
these cases (11.5%), disease manifestations were alreadypresent at birth, or began in the first day of life[1,6,11,14,17,29,34,46,51]. These cases are summarized inTable 1, where the proband of the family 1 (individual III.3,Fig. 1) and the twins of family 2 (individuals IV.3 and IV.4)were also included. We deliberately did not consider casesinformed as “neonatal onset”, since we would like to makesure that IPEX manifestations started in utero.
Considering the FOXP3 mutations listed in Table 1, onlythe family reported by Levy-Lahad & Wildin (cases 1–3,Table 1) [6,17] and the family 1 here described (Fig. 1) bearthe c.1189CNT mutation. Mutations detected in patients 4,5, 6, 8, 10 and 11 (Table 1) were described only once in theliterature. It is worth to note that mutations in the forkheadDNA-binding domain of FOXP3 were present in seven out offourteen cases listed in Table 1, i.e. cases 1–3 and cases 7,8, 11 and III.3.
Regarding the type of clinical manifestation at birth –here only live births were considered, i.e. the twins ofFamily 2 were excluded – 6/12 infants presented type-1diabetes mellitus, three presented diarrhea, and three hadgeneralized eczema as the most precocious feature. In thecase reported by Heltzer et al. [34] (patient 5, Table 1),the authors highlighted that “immediately after birth, hedeveloped copious green discharge from his rectum andnasogastric tube, which evolved to secretory diarrhea”. Thepresence of meconium in amniotic fluid of two preterminfants (cases 3 and III.3, Table 1), and of polyhydramnios inpatients 2 and 3, suggests that enteropathy could havebegun in utero. Among the 10 infants with information ongestational age, 9 were preterm ones. In eight patientswhere information on birth weight was available, four casesmay be classified as having intrauterine growth restriction(patients 2, 4, 9 and 12), and two (cases 2 and 4) presented asevere restriction (Z score b −3). Thus, premature labor andrestriction of fetal growth were frequent findings in thisgroup of infants, and reinforce our proposal that IPEX mayhave its onset in intrauterine life. Eleven of 12 patientslisted in Table 1 evolved to death, 9 of them in the first yearof life.
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
UNCO
R
4. Discussion
As we have previously pointed out, the findings with IPEXpatients, together with the equivalent mouse mutant scurfy,demonstrate that FOXP3 mutations affecting Treg celldevelopment and function critically impair immune peripheraltolerance and homeostasis [9,10,69–72]. Regulatory T cells,therefore, seem to ensure the central role in physiologicaltolerance to the body tissues. Thus, to the best of ourknowledge, all other mechanisms that participate in theprocess of natural tolerance (clonal deletion/anergy, “innate”sensing of “danger”, tissue-protective mechanisms and otherregulators of inflammation, etc.) are conserved, and yet, alltogether they fail to ensure tolerance in the absence of Tregs.The severity and the presence of IPEX autoimmune manifes-tations from the very beginning of life, on the other hand,demonstrate, if necessary it was, the marked “destructive”properties of the adaptive immune system.
The observations on the IPEX families here described addto those notions, showing that the powerful autoimmune
Please cite this article as: M.M. Xavier-da-Silva, et al., Fetal-onset IPEX: Rhttp://dx.doi.org/10.1016/j.clim.2014.12.007
ED P
RO
OF
process leading to disease and death may have its onset inintrauterine life, such that by birth a large damage to organsand tissues may have been established. Autoimmunediseases in fetal life are, indeed, extremely rare eventsand limited, thus far, to patients with IPEX and Omennsyndrome (OS), where a few patients with disease at birthhave been described [73–75]. Both conditions arelife-threatening diseases, and should be considered aspediatric emergencies [76,77]. Hence, all patients withautoimmune manifestations at birth (or suspected cases),should be investigated for these two PIDs that are stronglyassociated with autoimmune disease, and we have thusdesignated as monogenic autoimmune disorders. It mayseem surprising that “break of tolerance” can occur whenthe immune system is still immature. Rather than being“broken”, however, tolerance was never established, as wesuggest. The elegant experiments of Ohki and Le Douarin[78] demonstrated beyond doubt that the presence of tissuesand organs along with the development of an immune systemdoes not suffice to establish tolerance. In other words,establishment of natural tolerance requires appropriatethymic selection, as we know it now, for the commitmentand differentiation of auto-reactive Tregs [79,80].
In this context, and given the current knowledge on theage-dependent development of the various lymphocyte classesand effector functions, as well as on the ability of fetuses toproduce immune responses [80,81], it is not surprising thatpathological fetal autoimmunity exists, and that there is enoughtime before birth to produce auto-antibodies and high IgElevels, or for the destruction of pancreatic beta-cells. It isnoteworthy that T lymphocytes were observed infiltrating thepancreas of twin fetuses of 21 weeks of gestational age carryinga FOXP3 mutation (Fig. 3A). Although Langerhans islets werestill preserved, this lesion could be interpreted as an infiltrationby autorreactive T lymphocytes and an early stage of type 1diabetes mellitus [11].
Given the current conviction that fetuses are sterile (anotion that has been challenged, but remains widely accepted)[82], fetal disease, on the other hand, proves that “external” or“non-self” antigens, or the immune responses to them, are notnecessary for the establishment of autoimmune disease: in theabsence of Treg cells, the developing adaptive immune systemreacts to, and eliminates self-antigens. It is perhaps moresurprising, however, that severe intestinal inflammation anddestruction occur before birth, for there are several reportsclaiming that colonization by intestinal bacterial flora isnecessary in some experimental models of inflammatorybowel disease, involving cell transfers to immunodeficienthosts [83–85]. Keeping to the classical notion that the fetalintestine is not colonized, the repeated observations of severe,untreatable diarrhea frombirth, oftenwithmelenawithin a fewhours after delivery, of meconium in the amniotic fluid ofpreterm infants, all concur to the fact that intestinalautoimmune inflammation in IPEX may start before bacterialcolonization.
Although only one tenth of all described IPEX casespresented manifestations at birth (here included in Table 1),around 45% of the cases with information about “age ofonset” presented clinical manifestations in neonatal period,suggesting that fetal-onset autoimmunity in IPEX is not anuncommon phenomenon [4]. Regarding autoimmune cyto-penias in neonatal period, for example, the production of
eport of two families and review of literature, Clin. Immunol. (2014),
T
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441Q5
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483Q6
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
7Fetal-onset IPEX: Report of two families and review of literature
UNCO
RREC
autoantibodies probably had begun a couple of weeks before.On the other hand, the strong immune stimulation immedi-ately after birth – caused by the exposure to environmentalantigens – may trigger or amplify the underlying defects inimmune regulation/homeostasis, what could explain whyalmost all infants develop clinical features in the first weeks/months of life. Maternal Treg cells could play a role inregulation of the fetal immune system and thus delayingautoimmunemanifestations, either by crossing the placenta orby any other putative mechanism [80,86].
Regarding the possible relationships between the severity ofmutations and the occurrence of fetal-onset IPEX, our findingson the families here reported did not add significant under-standing to this topic, since data about the impact of these raremutations on protein expression or function are not yetavailable. However it is clear that both mutations severelyaffected gene transcription. The mutation c.1189CNT in exon12 alters the FOXP3 forkhead domain, a critical moleculardomain for suppressive Treg cell activity [72], and waspreviously described in another family also with fetal onsetand highly severe phenotype [6,17]. The novel mutationc.319_320delTC in exon 4 alters the translation frameshift, aspredicted by computational analysis.
We found no previous descriptions of multiple miscar-riages of males in IPEX families, although this kind of eventwas a relevant complaint in the two families reported in thispaper. Another distinctive feature of these families was thepresence of fetal hydrops in: i) the twins IV.3 and IV.4 infamily 2, in whom a FOXP3 mutation was identified, andii) individual III.2 in family I, presumptively affected by theFOXP3 mutation found in his mother and brother. IPEX hasnot yet been mentioned as a cause of fetal hydrops [87],however, in the cases here described, it is reasonable tocorrelate the anatomopathological findings with the pres-ence of FOXP3 mutations. Considering that hemolyticanemia is a well-known cause of hydrops and also a frequentIPEX manifestation [4], even in precocious cases, one canhypothesize that fetuses that develop autoimmune hemo-lytic anemia would evolve to hydrops and do not survive.Therefore, IPEX should be considered a cause of recurrentmiscarriages of male fetuses and of fetal hydrops.
In conclusion, the findings in the two families heredescribed, together with the 11 cases of IPEX at birthalready reported in literature, clearly show that autoim-mune aggression may occur already in utero, in a conditionwhere fetal functioning of natural Treg cells is severelyimpaired. Fetal-onset IPEX could represent a particularsubgroup of this disease, and certainly constitutes its mostsevere phenotype.
Conflict of interest statement
The authors declare that there are no conflicts of interest.
Acknowledgments
The authors are thankful to Silvia Yumi Bando, PhD, andFernanda B. Bertonha, PhD for skillful technical assistance inidentifying the FOXP3 mutations and help in revising themanuscript, to M. Claudia Zerbini, MD and Priscila PizzoCrêm dos Santos, for performing immunohistochemistry
Please cite this article as: M.M. Xavier-da-Silva, et al., Fetal-onset IPEX: Rhttp://dx.doi.org/10.1016/j.clim.2014.12.007
techniques, to Maria Teresa Seixas, MD, for the micropho-tographs showed in Fig. 3, and to all medical doctorsinvolved with the assistance and study of these families,particularly Dr. Diogo Soares, for his valuable help withfamily history, and to FAPESP (Fundação de Amparo àPesquisa do Estado de São Paulo) for financial support (grant2008/58.238-4).
ED P
RO
OF
References
[1] R.S. Wildin, S. Smyk-Pearson, A.H. Filipovich, Clinicaland molecular features of the immunodysregulation,polyendocrinopathy, enteropathy, X linked (IPEX) syndrome,J. Med. Genet. 39 (2002) 537–545.
[2] E. Gambineri, L. Perroni, L. Passerini, L. Bianchi, C. Doglioni,F. Meschi, et al., Clinical and molecular profile of a new seriesof patients with immune dysregulation, polyendocrinopathy,enteropathy, X-linked syndrome: inconsistent correlationbetween forkhead box protein 3 expression and diseaseseverity, J. Allergy Clin. Immunol. 122 (2008) 1105–1112.
[3] D. Moraes-Vasconcelos, B.T. Costa-Carvalho, T.R. Torgerson,H.D. Ochs, Primary immune deficiency disorders presenting asautoimmune diseases: IPEX and APECED, J. Clin. Immunol. 28(2008) S11–S19.
[4] F. Barzaghi, L. Passerini, R. Bacchetta, Immune dysregulation,polyendocrinopathy, enteropathy, x-linked syndrome: a paradigmof immunodeficiencywith autoimmunity, Front. Immunol. 3 (2012)211.
[5] C.L. Bennett, J. Christie, F. Ramsdell, P.J. Ferguson, L. Whitesell,et al., The immune dysregulation, polyendocrinopathy, enterop-athy, X-linked syndrome (IPEX) is caused by mutations of FOXP3,Nat. Genet. 27 (2001) 20–21.
[6] R.S. Wildin, F. Ramsdell, J. Peake, F. Faravelli, J.L. Casanova,N. Buist, et al., X-linked neonatal diabetes mellitus, enterop-athy and endocrinopathy syndrome is the human equivalent ofmouse scurfy, Nat. Genet. 27 (2001) 18–20.
[7] Y. Modigliani, A. Bandeira, A. Coutinho, A model for develop-mentally acquired thymus-dependent tolerance to central andperipheral antigens, Immunol. Rev. 149 (1996) 155-20.
[8] S. Hori, T. Nomura, S. Sakaguchi, Control of regulatory T celldevelopment by the transcription factor FOXP3, Science 299(2003) 1057–1061.
[9] S. Sakaguchi, T. Yamaguchi, T. Nomura, M. Ono, Regulatory Tcells and immune tolerance, Cell 133 (2008) 775–787.
[10] C. Benoist, D. Mathis, Treg cells, life history, and diversity,Cold Spring Harb. Symp. Quant. Biol. 4 (2012) a007021.
[11] B.T. Costa-Carvalho, M.I. De Moraes-Pinto, L.C. De Almeida,M.T. de Seixas Alves, R.P. Maia, R.L. de Souza, et al., Aremarkable depletion of both naive CD4+ and CD8+ with highproportion of memory T cells in an IPEX infant with a FOXP3mutation in the forkhead domain, Scand. J. Immunol. 68 (2008)85–91.
[12] M. Tsuda, T.R. Torgerson, C. Selmi, E. Gambineri, M. Carneiro-Sampaio, S.C. Mannurita, et al., The spectrum of autoantibodies inIPEX syndrome is broad and includes anti-mitochondrial autoanti-bodies, J. Autoimmun. 35 (2010) 265–268.
[13] E. d'Hennezel, K. Bin Dhuban, T. Torgerson, C.A. Piccirillo, Theimmunogenetics of immune dysregulation, polyendocrinopathy,enteropathy, X linked (IPEX) syndrome, J. Med. Genet. 49 (2012)291–302.
[14] N. Moes, F. Rieux-Laucat, B. Begue, J. Verdier, B. Neven, N. Patey,et al., Reduced expression of FOXP3 and regulatory T-cell functionin severe forms of early-onset autoimmune enteropathy, Gastro-enterology 139 (2010) 1770–1778.
[15] M. de Onis, C. Garza, A.W. Onyango, M.F. Rolland-Cachera, leComité de nutrition de la Société française de pédiatrie, WHO
eport of two families and review of literature, Clin. Immunol. (2014),
T
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
8 M.M. Xavier-da-Silva et al.
UNCO
RREC
growth standards for infants and young children, Arch. Pediatr.17 (2009) 47–53.
[16] I. Kobayashi, R. Shiari, M. Yamada, N. Kawamura, M. Okano, A.Yara, et al., Novel mutations of FOXP3 in two Japanese patientswith immune dysregulation, polyendocrinopathy, enteropathy, Xlinked syndrome (IPEX), J. Med. Genet. 38 (2001) 874–876.
[17] E. Levy-Lahad, R.S. Wildin, Neonatal diabetes mellitus,enteropathy, thrombocytopenia, and endocrinopathy: furtherevidence for an X-linked lethal syndrome, J. Pediatr. 138(2001) 577–580.
[18] J.E. Peake, R.B. Mccrossin, G. Byrne, R. Shepherd, X-linkedimmune dysregulation, neonatal insulin dependent diabetes,and intractable diarrhoea, Arch. Dis. Child. Fetal Neonatal Ed.74 (1996) F195–F199.
[19] T.A. Chatila, F. Blaeser, N. Ho, H.M. Lederman, C.Voulgaropoulos, C. Helms, et al., JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergicdysregulation syndrome, J. Clin. Invest. 106 (2000) R75–R81.
[20] P.J. Ferguson, S.H. Blanton, F.T. Saulsbury, M.J. McDuffie, V.Lemahieu, J.M. Gastier, et al., Manifestations and linkageanalysis in X-linked autoimmunity-immunodeficiency syn-drome, Am. J. Med. 90 (2000) 390–397.
[21] O. Baud, O. Goulet, D. Canioni, F. Le Deist, I. Radford, D. Rieu,et al., Treatment of the immune dysregulation,polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) byallogeneic bone marrow transplantation, N. Engl. J. Med. 344(2001) 1758–1762.
[22] C.J. Owen, C.E. Jennings, H. Imrie, A. Lachaux, N.A. Bridges, T.D.Cheetham, et al., Mutational analysis of the FOXP3 gene andevidence for genetic heterogeneity in the immunodysregulation,polyendocrinopathy, enteropathy syndrome, J. Clin. Endocrinol.Metab. 88 (2003) 6034–6039.
[23] D.S. Nieves, R.P. Phipps, S.J. Pollock, H.D. Ochs, Q. Zhu, G.A.Scott, et al., Dermatologic and immunologic findings in theimmune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome, Arch. Dermatol. 140 (2004) 466–472.
[24] H. Tanaka, K. Tsugawa, M. Kudo, K. Sugimoto, I. Kobayashi, E.Ito, et al., Low-dose cyclosporine A in a patient with X-linkedimmune dysregulation, polyendocrinopathy and enteropathy,Eur. J. Pediatr. 164 (2005) 779–780.
[25] L. Bindl, T. Torgerson, L. Perroni, N. Youssef, H.D. Ochs, O.Goulet, F.M. Ruemmele, et al., Successful use of the newimmune-suppressor sirolimus in IPEX (immune dysregulation,polyendocrinopathy, enteropathy, X-linked syndrome), J.Pediatr. 147 (2005) 256–259.
[26] E. Mazzolari, C. Forino, M. Fontana, C. D'Ippolito, A. Lanfranchi, E.Gambineri, et al., A new case of IPEX receiving bone marrowtransplantation, Bone Marrow Transplant. 35 (2005) 1033–1034.
[27] R. Bacchetta, L. Passerini, E. Gambineri, M. Dai, S.E. Allan, L.Perroni, et al., Defective regulatory and effector T cell functions inpatients with FOXP3 mutations, J. Clin. Invest. 116 (2006)1713–1722.
[28] F. De Benedetti, A. Insalaco, A. Diamanti, E. Cortis, F. Muratori, A.Lamioni, et al., Mechanistic associations of a mild phenotype ofimmunodysregulation, polyendocrinopathy, enteropathy, x-linkedsyndrome, Clin. Gastroenterol. Hepatol. 4 (2006) 653–659.
[29] A.K. Myers, L. Perroni, C. Costigan, W. Reardon, Clinical andmolecular findings in IPEX syndrome, Arch. Dis. Child. 91 (2006)63–64.
[30] M.A. Gavin, T.R. Torgerson, E. Houston, P. DeRoos, W.Y. Ho, A.Stray-Pedersen, et al., Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T celldevelopment, Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 6659–6664.
[31] J.L. McGinness, M.M. Bivens, K.E. Greer, J.W. Patterson, F.T.Saulsbury, Immune dysregulation, polyendocrinopathy, enter-opathy, X-linked syndrome (IPEX) associated with pemphigoidnodularis: a case report and review of the literature, J. Am.Acad. Dermatol. 55 (2006) 143–148.
Please cite this article as: M.M. Xavier-da-Silva, et al., Fetal-onset IPEX: Rhttp://dx.doi.org/10.1016/j.clim.2014.12.007
ED P
RO
OF
[32] L.M. Burroughs, R. Storb, W.M. Leisenring, M.A. Pulsipher, M.R.Loken, T.R. Torgerson, et al., Intensive postgrafting immunesuppression combined with nonmyeloablative conditioning fortransplantation of HLA-identical hematopoietic cell grafts:results of a pilot study for treatment of primary immunodefi-ciency disorders, Bone Marrow Transplant. 40 (2007) 633–642.
[33] T. Fuchizawa, Y. Adachi, Y. Ito, H. Higashiyama, H. Kanegane, T.Futatani, et al., Developmental changes of FOXP3-expressingCD4+CD25+ regulatory T cells and their impairment in patientswith FOXP3 gene mutations, Clin. Immunol. 125 (2007) 237–246.
[34] M.L. Heltzer, J.K. Choi, H.D. Ochs, K.E. Sullivan, T.R.Torgerson, L.M. Ernst, et al., A potential screening tool forIPEX syndrome, Pediatr. Dev. Pathol. 10 (2007) 98–105.
[35] K.G. Lucas, D. Ungar, M. Comito, M. Bayerl, B. Groh,Submyeloablative cord blood transplantation corrects clinicaldefects seen in IPEX syndrome, Bone Marrow Transplant. 39(2007) 55–56.
[36] P. McLucas, G.J. Fulchiero Jr., E. Fernandez, J.J. Miller, A.L.Zaenglein, Norwegian scabies mimicking onychomycosis andscalp dermatitis in a child with IPEX syndrome, J. Am. Acad.Dermatol. 56 (2007) S48–S49.
[37] A. Moudgil, P. Perriello, B. Loechelt, R. Przygodzki, W. Fitzerald,N. Kamani, et al., Immunodysregulation, polyendocrinopathy,enteropathy, X-linked (IPEX) syndrome: an unusual cause ofproteinuria in infancy, Pediatr. Nephrol. 22 (2007) 1799–1802.
[38] A. Rao, N. Kamani, A. Filipovich, S.M. Lee, S.M. Davies, J.Dalal, et al., Successful bone marrow transplantation for IPEXsyndrome after reduced-intensity conditioning, Blood 109(2007) 383–385.
[39] S. Suzuki, Y. Makita, T. Mukai, K. Matsuo, O. Ueda, K. Fujieda,et al., Molecular basis of neonatal diabetes in Japanese patients,J. Clin. Endocrinol. Metab. 92 (2007) 3979–3985.
[40] A. Taddio, E. Faleschini, E. Valencic, M. Granzotto, A.Tommasini, L. Lepore, et al., Medium-term survival withouthaematopoietic stem cell transplantation in a case of IPEX:insights into nutritional and immunosuppressive therapy, Eur. J.Pediatr. 166 (2007) 1195–1197.
[41] T.R. Torgerson, A. Linane, N. Moes, S. Anover, V. Mateo, F.Rieux-Laucat, et al., Severe food allergy as a variant of IPEXsyndrome caused by a deletion in a noncoding region of theFOXP3 gene, Gastroenterology 132 (2007) 1705–1717.
[42] K.G. Lucas, D. Ungar, M. Comito, B. Groh, Epstein Barr virusinduced lymphoma in a child with IPEX syndrome, Pediatr.Blood Cancer 50 (2008) 1056–1057.
[43] P.L. Yong, P. Russo, K.E. Sullivan, Use of sirolimus in IPEX andIPEX-like children, J. Clin. Immunol. 28 (2008) 581–587.
[44] H. Zhan, J. Sinclair, S. Adams, C.M. Cale, S. Murch, L. Perroni,et al., Immune reconstitution and recovery of FOXP3 (forkheadbox P3)-expressing T cells after transplantation for IPEX(immune dysregulation, polyendocrinopathy, enteropathy, X-linked) syndrome, Pediatrics 121 (2008) e998–e1002.
[45] M.J. Dorsey, A. Petrovic, M.R. Morrow, L.J. Dishaw, J.W.Sleasman, FOXP3 expression following bone marrow transplan-tation for IPEX syndrome after reduced-intensity conditioning,Immunol. Res. 44 (2009) 179–184.
[46] E. D'Hennezel, M. Ben-Shoshan, H.D. Ochs, et al., FOXP3forkhead domain mutation and regulatory T cells in the IPEXsyndrome, N. Engl. J. Med. 361 (2009) 1710–1713.
[47] M. Halabi-Tawil, F.M. Ruemmele, S. Fraitag, F. Rieux-Laucat,B. Neven, B. Brousse, et al., Cutaneous manifestations ofimmune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, Br. J. Dermatol. 160 (2009) 645–651.
[48] Y. Hashimura, K. Nozu, H. Kanegane, Minimal changenephrotic syndrome associated with immune dysregulation,polyendocrinopathy, enteropathy, X-linked syndrome, Pediatr.Nephrol. 24 (2009) 1181–1186.
[49] N. Patey-Mariaud de Serre, D. Canioni, S. Ganousse, F.Rieux-Laucat, O. Goulet, F. Ruemmele, et al., Digestive
eport of two families and review of literature, Clin. Immunol. (2014),
T
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
9Fetal-onset IPEX: Report of two families and review of literature
UNCO
RREC
histopathological presentation of IPEX syndrome, Mod.Pathol. 22 (2009) 95–102.
[50] A.R. Redding, D.B. Lew, M.E. Conley, E.K. Pivnick, An infantwith erythroderma, skin scaling, chronic emesis, and intracta-ble diarrhea, Clin. Pediatr. (Phila.) 48 (2009) 978–980.
[51] O. Rubio-Cabezas, J.A. Minton, R. Caswell, J.P. Shield, D.Deiss, Z. Sumnik, et al., Clinical heterogeneity in patients withFOXP3 mutations presenting with permanent neonatal diabe-tes, Diabetes Care 32 (2009) 111–116.
[52] M. Scaillon, S. Van Biervliet, P. Bontems, H. Dorchy, L.Hanssens, A. Ferster, et al., Severe gastritis in an insulin-dependent child with an IPEX syndrome, J. Pediatr.Gastroenterol. Nutr. 49 (2009) 368–370.
[53] L.M. Burroughs, T.R. Torgerson, R. Storb, P.A. Carpenter, D.J.Rawlings, J. Sanders, et al., Stable hematopoietic cell engraft-ment after low-intensity nonmyeloablative conditioning inpatients with immune dysregulation, polyendocrinopathy, enter-opathy, X-linked syndrome, J. Allergy Clin. Immunol. 126 (2010)1000–1005.
[54] R. Harbuz, J. Lespinasse, S. Boulet, C. Francannet, I.Creveaux, M. Benkhelifa, et al., Identification of new FOXP3mutations and prenatal diagnosis of IPEX syndrome, Prenat.Diagn. 30 (2010) 1072–1078.
[55] A.N. McMurchy, J. Gillies, S.E. Allan, L. Passerini, E.Gambineri, M.G. Roncarolo, et al., Point mutants of forkheadbox P3 that cause immune dysregulation, polyendocrinopathy,enteropathy, X-linked have diverse abilities to reprogram Tcells into regulatory T cells, J. Allergy Clin. Immunol. 126(2010) 1242–1251.
[56] J. Wang, X. Li, Z. Jia, Y. Tian, J. Yu, L. Bao, et al., ReducedFOXP3 expression causes IPEX syndrome onset: an implicationfrom an IPEX patient and his disease-free twin brother, Clin.Immunol. 137 (2010) 178–180.
[57] Y.F. An, F. Xu, M. Wang, Z.Y. Zhang, X.D. Zhao, Clinicaland molecular characteristics of immunodysregulation,polyendocrinopathy, enteropathy, X-linked syndrome inChina, Scand. J. Immunol. 74 (2011) 304–309.
[58] K.W. Bae, B.E. Kim, J.H. Choi, J.H. Lee, Y.S. Park, G.H. Kim,et al., A novel mutation and unusual clinical features in apatient with immune dysregulation, polyendocrinopathy, en-teropathy, X-linked (IPEX) syndrome, Eur. J. Pediatr. 170(2011) 1611–1615.
[59] K.A. Kasow, V.M. Morales-Tirado, D. Wichlan, S.A. Shurtleff, A.Abraham, D.A. Persons, et al., Therapeutic in vivo selection ofthymic-derived natural T regulatory cells following non-myeloablative hematopoietic stem cell transplant for IPEX,Clin. Immunol. 141 (2011) 169–176.
[60] I. Kobayashi, M. Kubota, M. Yamada, H. Tanaka, S. Itoh, Y.Sasahara, L. Whitesell, et al., Autoantibodies to villin occurfrequently in IPEX, a severe immune dysregulation, syndromecaused by mutation of FOXP3, Clin. Immunol. 141 (2011)83–89.
[61] S.I. Lopez, M. Ciocca, M. Oleastro, M.L. Cuarterolo, A. Rocca, M.T.de Dávila, et al., Autoimmune hepatitis type 2 in a child with IPEXsyndrome, J. Pediatr. Gastroenterol. Nutr. 53 (2011) 690–693.
[62] K. Otsubo, H. Kanegane, Y. Kamachi, I. Kobayashi, I. Tsuge, M.Imaizumi, et al., Identification of FOXP3-negative regulatoryT-like (CD4(+)CD25(+)CD127(low)) cells in patients with im-mune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome, Clin. Immunol. 141 (2011) 111–120.
[63] L. Passerini, S. Di Nunzio, S. Gregori, E. Gambineri, M. Cecconi,M.G. Seidel, et al., Functional type-1 regulatory T cellsdevelop regardless of FOXP3 mutations in patients with IPEXsyndrome, Eur. J. Immunol. 41 (2011) 1120–1131.
[64] L. Passerini, S. Olek, S. Di Nunzio, F. Barzaghi, S. Hambleton,M. Abinun, et al., Forkhead box protein 3 (FOXP3) mutationslead to increased TH17 cell numbers and regulatory T-cellinstability, J. Allergy Clin. Immunol. 128 (2011) 1376–1379.
Please cite this article as: M.M. Xavier-da-Silva, et al., Fetal-onset IPEX: Rhttp://dx.doi.org/10.1016/j.clim.2014.12.007
ED P
RO
OF
[65] A. Martín-Santiago, J.A. Hervás, D. Hervás, A. Rosell, M.Caimari, J.C. de Carlos, et al., Diagnostic value of the skinlesions in immune dysregulation, polyendocrinopathy, enter-opathy, X-linked syndrome, Pediatr. Dermatol. 30 (2013)221–222.
[66] R. Rodrigo, N. Atapattu, K.S. de Silva, IPEX syndrome withmembrano-proliferative nephrotic syndrome, Ceylon Med. J.58 (2013) 43–44.
[67] A. Boldt, K. Kentouche, S. Fricke, S. Borte, F. Kahlenberg, U.Sack, et al., Differences in FOXP3 and CD127 expression inTreg-like cells in patients with IPEX syndrome, Clin. Immunol.153 (2014) 109–111.
[68] B.R. Powell, N.R. Buist, P. Stenzel, An X-linked syndrome ofdiarrhea, polyendocrinopathy, and fatal infection in infancy, J.Pediatr. 100 (1982) 731–737.
[69] A. Coutinho, W. Haas, In vivo models of dominant T-celltolerance: where do we stand today? Trends Immunol. 22(2001) 350–351.
[70] A. Coutinho, S. Hori, T. Carvalho, I. Caramalho, J. Demengeot,Regulatory T cells: the physiology of autoreactivity in domi-nant tolerance and “quality control” of immune responses,Immunol. Rev. 182 (2001) 89–98.
[71] M.A. Curotto de Lafaille, J.J. Lafaille, Natural and adaptiveFOXP3+ regulatory T cells: more of the same or a division oflabor? Immunity 30 (2009) 626–635.
[72] F. Ramsdell, S.F. Ziegler, FOXP3 and scurfy: how it all began,Nat. Rev. Immunol. 14 (2014) 343–349.
[73] C.A. Zago, C.M. Jacob, E.M. Diniz, S.M. Lovisolo, M.C. Zerbini,M. Dorna, et al., Autoimmune manifestations in SCID due toIL7R mutations: Omenn syndrome and cytopenias, Hum.Immunol. 75 (2014) 662–666.
[74] N. Aladangady, S. Kinmond, A.J. Cant, B. Gibson, J.A. Coutts,A preterm baby with Omenn syndrome, Eur. J. Pediatr. 159(2000) 657–658.
[75] E. Puzenat, P. Rohrlich, P. Thierry, P. Girardin, M. Taghian, M.Ouachee, et al., Omenn syndrome: a rare case of neonatalerythroderma, Eur. J. Dermatol. 17 (2007) 137–139.
[76] M. Carneiro-Sampaio, A. Coutinho, Tolerance and autoimmu-nity: lessons at the bedside of primary immunodeficiencies,Adv. Immunol. 95 (2007) 51–82.
[77] G. Bussone, L. Mouthon, Autoimmune manifestations inprimary immune deficiencies, Autoimmun. Rev. 8 (2009)332–336.
[78] H. Ohki, C. Martin, C. Corbel, M. Coltey, M.M. Le Douarin,Effect of early embryonic grafting of foreign tissues on theimmune response of the host, Prog. Clin. Biol. Res. 307 (1989)3–17.
[79] A. Coutinho, I. Caramalho, E. Seixas, J. Demengeot, Thymiccommitment of regulatory T cells is a pathway of TCR-dependent selection that isolates repertoires undergoingpositive or negative selection, Curr. Top. Microbiol. Immunol.293 (2005) 43–71.
[80] J.E. Mold, J.M. McCune, Immunological tolerance during fetaldevelopment: from mouse to man, Adv. Immunol. 115 (2012)73–111.
[81] D.B. Lewis, C.B. Wilson, Developmental immunology and roleof host defenses in fetal and neonatal susceptibility toinfection, in: J.S. Remington, J.O. Klein, C.B. Wilson, V.Nizet, Y.A. Maldonado (Eds.), Infectious Diseases of the Fetusand Newborn Infant, 7th ed.Elsevier Saunders, 2011,pp. 80–191.
[82] L. Moles, M. Gómez, H. Heilig, G. Bustos, S. Fuentes, W.de Vos, et al., Bacterial diversity in meconium of pretermneonates and evolution of their fecal microbiota during thefirst month of life, PLoS One 8 (2013) e66986.
[83] R.B. Sartor, Targeting enteric bacteria in treatment ofinflammatory bowel diseases: why, how, and when, Curr.Opin. Gastroenterol. 19 (2003) 358–365.
eport of two families and review of literature, Clin. Immunol. (2014),
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
10 M.M. Xavier-da-Silva et al.
[84] E. Cario, Microbiota and innate immunity in intestinal inflamma-tion and neoplasia, Curr. Opin. Gastroenterol. 29 (2013) 85–91.
[85] K.K. Gkouskou, C. Deligianni, C. Tsatsanis, A.G. Eliopoulos,The gut microbiota in mouse models of inflammatory boweldisease, Front. Cell. Infect. Microbiol. 4 (2014) 28.
[86] J.E. Mold, J. Michaëlsson, T.D. Burt, M.O. Muench, K.P.Beckerman, M.P. Busch, et al., Maternal alloantigens promote
UNCO
RRECT
Please cite this article as: M.M. Xavier-da-Silva, et al., Fetal-onset IPEX: Rhttp://dx.doi.org/10.1016/j.clim.2014.12.007
the development of tolerogenic fetal regulatory t cells inutero, Science 322 (2008) 1562–1565.
[87] V. Désilets, F. Audibert, Society of obstetrician andgynaecologists of Canada, investigation and management ofnon-immune fetal hydrops, J. Obstet. Gynaecol. Can. 35 (2013)923–938.
ED P
RO
OF
eport of two families and review of literature, Clin. Immunol. (2014),